A clinical case report published in 2020 reported for the first time the achievement of a good response to cabozantinib plus nivolumab therapy in an HCC patient with bone metastasis with RET amplification, copy number of 5, TMB ≥ 10 mutations/megabase and high PD-L1 expression [129]. The gene discussed is CD274; the disease is hepatocellular carcinoma.